Advaxis (NASDAQ: ADXS) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Advaxis to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, valuation, risk and earnings.
Volatility & Risk
Advaxis has a beta of 1.98, indicating that its share price is 98% more volatile than the S&P 500. Comparatively, Advaxis’ peers have a beta of 1.54, indicating that their average share price is 54% more volatile than the S&P 500.
This table compares Advaxis and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Advaxis and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Advaxis||$3.99 million||-$73.55 million||-1.30|
|Advaxis Competitors||$215.30 million||-$39.34 million||-77.95|
Advaxis’ peers have higher revenue and earnings than Advaxis. Advaxis is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
41.4% of Advaxis shares are held by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 7.2% of Advaxis shares are held by company insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of current ratings for Advaxis and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Advaxis presently has a consensus price target of $21.00, indicating a potential upside of 604.70%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.36%. Given Advaxis’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Advaxis is more favorable than its peers.
Advaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.